China has become the world’s second largest pharmaceutical consumer market

National Food and Drug Administration Deputy Director Wu Zhen 12, said that after years of development, China has become the world’s second largest pharmaceutical consumer market, the largest export of bulk drugs.Benzalkonium chloride

Wu Zhen held in the day of the 2017 developing countries drug quality management seminar classes said that China’s existing nearly 5,000 raw materials and pharmaceutical companies, pharmaceutical manufacturing annual main business income of more than 2.5 trillion yuan, of which Nearly 50 pharmaceutical companies through the European and American certification or inspection, pharmaceutical manufacturing exports more than 13.5 billion US dollars, indicating that China’s pharmaceutical industry already has the rest of the world to provide safe and reliable pharmaceutical products.

In 2015, the Chinese female drug scientist Tu Yo Yo won the Nobel Prize in Physiology or Medicine. Wu Zhen pointed out that China’s pharmaceutical industry is to contribute to the development of innovative drugs around the world, in the field of global disease prevention and health protection play a positive role. As a first-line antimalarial drug recommended by the World Health Organization, artemisinin has saved millions of lives in the world, especially in developing countries, and this discovery is called “the greatest medical pioneer in the second half of the twentieth century”.

Wu Zhen also pointed out that China in the pharmaceutical economy and drug regulation is still some problems, such as drug research and development, production, circulation and use of regional imbalance between the existence of regional regulation of drug regulation and other issues. In addition, with the rapid development of science and technology, drugs in research and development, production and use of diversity and complexity.

In order to speed up the speed of drug review and approval, to solve the backlog of drug registration, Food and Drug Administration this year in the drug review and approval system reform to take further measures to achieve good results. Wu Zhen pointed out that the Food and Drug Administration has redefined the definition and classification of new drugs, clear the generic drug must be consistent with the original drug quality evaluation criteria, the establishment of a clinical efficacy-oriented drug review system, emphasizing pharmacy, Technology, quality, based on the focus on drug clinical trial results to ensure that the clinical efficacy of listed drugs.